What Eikon’s modest IPO says about the future of big-money, big-name biotech - Endpoints News
Source:Endpoints.news
Eikon Therapeutics IPOs at $971M valuation, down nearly 75% from peak, raising $381M despite Nobel Prize science backing and leadership by ex-Merck exec Roger Perlmutter.
Related Articles
Capital One acquires Brex for a steep discount to its peak valuation, but early believers are laughing all the way to the bank - TechCrunch
Before everyone sharpens their knives, consider that for the VCs who backed Brex at its outset, the …
Judge says construction on Vineyard Wind can resume - wbur.org
A federal judge issued a temporary pause on a Trump administration order that halted construction on …
Gold and Silver Prices Fall Sharply as Trump Picks Warsh as Fed Chair. Here’s Why. - Barron's
Bessent Says Powell Attending Supreme Court Hearing Is ‘Mistake’ - Bloomberg
Treasury Secretary Scott Bessent criticized Federal Reserve Chair Jerome Powell over his plans to …